Related Experiment Video
Updated: May 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Cancer syndromes and therapy by stop-codon readthrough
Renata Bordeira-Carriço1, Ana Paula Pêgo, Manuel Santos
1Institute of Molecular Pathology and Immunology of the University of Porto, Portugal.
Readthrough strategies can restore protein function in hereditary cancer syndromes caused by premature termination codons (PTC). This review explores therapeutic potential and challenges like nonsense-mediated decay.
Area of Science:
- Genetics
- Molecular Biology
- Oncology
Background:
- Hereditary cancer syndromes often arise from nonsense mutations creating premature termination codons (PTCs).
- Restoring functional protein expression is a key therapeutic goal for these genetic disorders.
- Current research explores various strategies to overcome the effects of PTCs.
Purpose of the Study:
- To review the potential of readthrough strategies for treating cancer syndromes associated with PTCs.
- To discuss the efficacy and challenges of different readthrough induction methods.
- To analyze factors influencing readthrough efficiency, including nonsense-mediated decay.
Main Methods:
- Literature review of therapeutic strategies for PTC-associated diseases.
- Analysis of small molecules (e.g., aminoglycosides, PTC124) and genetic approaches (e.g., suppressor-tRNAs).
- Evaluation of factors affecting readthrough efficiency in cancer contexts.
Main Results:
- Readthrough induction strategies show promise in preclinical models for genetic diseases like cystic fibrosis and Duchenne muscular dystrophy.
- Various methods, including small molecules and genetic manipulations, can induce readthrough of PTCs.
- Nonsense-mediated decay (NMD) and other cellular mechanisms can significantly impact the efficiency of readthrough therapies.
Conclusions:
- Readthrough strategies represent a viable therapeutic avenue for hereditary cancer syndromes linked to PTCs.
- Optimizing readthrough efficiency and overcoming resistance mechanisms like NMD are critical for clinical success.
- Further research is needed to fully harness the potential of readthrough therapies for cancer treatment.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

